EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel By Ogkologos - August 26, 2025 84 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Study Shows that Disrupted Gut Bacteria May Contribute to the Spread... June 21, 2019 New Mom Was Told a Lump in Her Breast Was “Built-Up... April 5, 2019 A New Online Tool Predicts RFS and OS Probabilities in Patients... February 7, 2024 Mortality From PSA-Detected Localised Prostate Cancer Remains Very Low Regardless of... March 21, 2023 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Trastuzumab Deruxtecan Stage IV Cancer Patient Clinging to Life Overseas While Family Raises... Cancer Survivor And His Organ Donor Run NYC Marathon Together To... How to Find an Oncologist Who’s an LGBTQ+ Ally: An Expert...
